A preemptive low dose of the nonsteroidal anti-inflammatory drug (NSAID) etoricoxib may reduce the need for analgesics after third-molar surgery, based on the results of a randomized clinical trial ...
The US FDA has deemed that the new selective COX-2 inhibitor, etoricoxib (Arcoxia ®, Merck & Co), is "approvable" but says that additional data on safety and efficacy are required before the approval ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Washington DC - An FDA memo shows that there are concerns over an increase in cardiovascular risk with 2 new COX-2 selective inhibitors that are awaiting approval in the US—etoricoxib (Arcoxia, Merck ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results